CNBX Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is September - August.

Millions USD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 28, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Net Income	-0.37	-0.31	-0.7	-3.71	-3.72	-3.19
Depreciation & Amortization	-	-	0.07	0.16	0.2	0.22
Loss (Gain) From Sale of Investments	-	-	0.09	2.73	-0.01	-0.2
Stock-Based Compensation	-	-	0.14	0.18	0.73	0.03
Other Operating Activities	0.05	0.04	0.02	0.05	0.72	0.71
Change in Accounts Receivable	0	0	0.09	-0.01	0.12	-0.01
Change in Accounts Payable	0.16	0.1	0.04	0.49	0.28	-0.05
Operating Cash Flow	-0.16	-0.17	-0.24	-0.11	-1.68	-2.49
Capital Expenditures	-	-	-0	-	-0	-0
Sale of Property, Plant & Equipment	-	-	0.11	-	0.03	-
Investment in Securities	-	-	-	0.02	-	0.65
Investing Cash Flow	-	-	0.11	0.02	0.03	0.65
Short-Term Debt Issued	-	0.16	0.03	0.1	0.39	2.46
Total Debt Issued	0.13	0.16	0.03	0.1	0.39	2.46
Net Debt Issued (Repaid)	0.13	0.16	0.03	0.1	0.39	2.46
Financing Cash Flow	0.13	0.16	0.03	0.1	0.39	2.46
Foreign Exchange Rate Adjustments	-	-	-	-	-0	-
Net Cash Flow	-0.03	-0.01	-0.1	0.01	-1.27	0.61
Free Cash Flow	-0.16	-0.17	-0.25	-0.11	-1.68	-2.49
Free Cash Flow Margin	-	-	-188.71%	-27.43%	-5610.68%	-
Free Cash Flow Per Share	-	-0.00	-0.01	-0.01	-1.38	-2.16
Levered Free Cash Flow	-0.06	-0.09	-0.03	0.23	-0.51	-1.48
Unlevered Free Cash Flow	-0.03	-0.07	-0.02	0.23	-0.51	-1.48
Change in Working Capital	0.16	0.1	0.13	0.47	0.41	-0.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.